Prostaglandin I2 analogues suppress TNF-α expression in human monocytes via mitogen-activated protein kinase pathway

Inflammation Research

Volumn 60, Issue 7, 2011, Pages 655-663

  Wang, Wei Li ^a,b   Kuo, Chang Hung ^a,b,c   Chu, Yu Te ^a,b   Huang, Ching Hua ^f   Lam, Ka Pan ^d   Huang, Shau Ku ^g   Jong, Yuh Jyh ^a,b,e   Kuo, Yu Ting ^a,b,c   Hung, Chih Hsing ^a,c,e  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MUNICIPAL TA TUNG HOSPITAL   (Taiwan)

^d PINGTUNG CHRISTIAN HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^f YUAN'S GENERAL HOSPITAL   (Taiwan)

^g JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

Author keywords

I prostanoid receptor; MAPK pathway; Monocytes; Prostaglandin I2; Tumor necrosis factor a

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ADENYLATE CYCLASE; BERAPROST; CYCLIC AMP; FORSKOLIN; ILOPROST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTACYCLIN; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 4; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNIPROST;

ARTICLE; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MONOCYTE; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CELL LINE; EPOPROSTENOL; HUMANS; ILOPROST; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; MONOCYTES; PPAR GAMMA; TUMOR NECROSIS FACTOR-ALPHA; VASODILATOR AGENTS;

EID: 80051670610     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-011-0317-6     Document Type: Article

References (20)

1. Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, McConnell W, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax. 2005;60:1012-8. (Pubitemid 41705469)
2. Broide DH, Lotz M, Cuomo AJ, Coburn DA, Federman EC, Wasserman SI. Cytokines in symptomatic asthma airways. J Allergy Clin Immunol. 1992;89:958-67.
3. Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol. 2008;121:5-10. quiz 1-2.
4. Franchimont D, Martens H, Hagelstein MT, Louis E, Dewe W, Chrousos GP, et al. Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor. J Clin Endocrinol Metab. 1999;84:2834-9. (Pubitemid 30642019)
5. Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med. 2006;354:697-708. (Pubitemid 43247140)
6. Badesch DB, McLaughlin VV, Delcroix M, Vizza CD, Olschewski H, Sitbon O, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:56S-61S. (Pubitemid 38759718)
7. Nagao K, Tanaka H, Komai M, Masuda T, Narumiya S, Nagai H. Role of prostaglandin I2 in airway remodeling induced by repeated allergen challenge in mice. Am J Respir Cell Mol Biol. 2003;29:314-20. (Pubitemid 37093989)
8. Idzko M, Hammad H, van Nimwegen M, Kool M, Vos N, Hoogsteden HC, et al. Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function. J Clin Invest. 2007;117:464-72. (Pubitemid 46203975)
9. 2 analogues. Eur Respir J. 2009;33:405-10.
10. Czeslick EG, Simm A, Grond S, Silber RE, Sablotzki A. Inhibition of intracellular tumour necrosis factor (TNF)-alpha and interleukin (IL)-6 production in human monocytes by iloprost. Eur J Clin Invest. 2003;33:1013-7. (Pubitemid 37421601)
11. Kuo CH, Ko YC, Yang SN, Chu YT, Wang WL, Huang SK, et al. Effects of PGI(2) analogues on Th1- and Th2-related chemokines in monocytes via epigenetic regulation. J Mol Med. 2011; 89:29-41.
12. Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 2007;28:551-8. (Pubitemid 350101420)
13. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal. 2001;13:85-94. (Pubitemid 32222977)
14. Hung CH, Suen JL, Hua YM, Chiang W, Chang HC, Chen CN, et al. Suppressive effects of ketotifen on Th1- and Th2-related chemokines of monocytes. Pediatr Allergy Immunol. 2007;18:378-84. (Pubitemid 47037909)
15. Serra-Batlles J, Plaza V, Morejon E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J. 1998;12:1322-6. (Pubitemid 29011423)
16. Burgess JK, Ge Q, Boustany S, Black JL, Johnson PR. Increased sensitivity of asthmatic airway smooth muscle cells to prostaglandin E2 might be mediated by increased numbers of E-prostanoid receptors. J Allergy Clin Immunol. 2004;113: 876-81. (Pubitemid 38608596)
17. Jaffar Z, Ferrini ME, Buford MC, Fitzgerald GA, Roberts K. Prostaglandin I2-IP signaling blocks allergic pulmonary inflammation by preventing recruitment of CD4+ Th2 cells into the airways in a mouse model of asthma. J Immunol. 2007;179: 6193-203.
18. Aronoff DM, Peres CM, Serezani CH, Ballinger MN, Carstens JK, Coleman N, et al. Synthetic prostacyclin analogs differentially regulate macrophage function via distinct analog-receptor binding specificities. J Immunol. 2007;178:1628-34. (Pubitemid 46154634)
19. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J. 2008;31:891-901.
20. Zhou W, Hashimoto K, Goleniewska K, O'Neal JF, Ji S, Blackwell TS, et al. Prostaglandin I2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells. J Immunol. 2007;178:702-10. (Pubitemid 46095142)